Browsing: Viral > HIV / AIDS
Declining HIV diagnoses in the UK have been highlighted in a recent report from Public Health England, meaning that for the first time UN targets have been reached.
Take a look behind the scenes of a recent Future Virology paper as we ask author Darrell Tan about the potential of pre-exposure prophylaxis (PrEP) for HIV prevention, PrEP failure and what research is needed in the field.
Antiretroviral therapy with efavirenz in HIV-positive pregnant women has been reported to increase the risk of neurological conditions in offspring.
A recent study carried out by researchers from the University of Zurich and University Hospital Zurich has discovered that the production of broad acting antibodies is dependent on the genome of the virus.
Financial modelling has been used to estimate the costs and likelihood of candidate medicines, vaccines, diagnostics and technologies launching, revealing gaps in the pipeline and in funding.
ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
Experimental HIV-1 vaccine regimen is safe and elicits a robust immune response according to results of a Phase I/IIa clinical trial.